Spaces:
Running
Running
hiverlab-nicholastkb
commited on
Commit
·
387d6d7
1
Parent(s):
fb83628
Updated app.py
Browse files
app.py
CHANGED
@@ -67,14 +67,14 @@ def visualize_entities(sentence):
|
|
67 |
import gradio as gr
|
68 |
|
69 |
exampleList = [
|
70 |
-
'
|
|
|
71 |
'A randomized Phase III trial demonstrated noninferiority of APF530 500 mg SC ( granisetron 10 mg ) to intravenous palonosetron 0.25 mg in preventing CINV in patients receiving MEC or HEC in acute ( 0 - 24 hours ) and delayed ( 24 - 120 hours ) settings , with activity over 120 hours .',
|
72 |
'What are the known interactions between Aspirin and the COX-1 enzyme?',
|
73 |
'Can you explain the mechanism of action of Metformin and its effect on the AMPK pathway?',
|
74 |
'Are there any genetic variations in the CYP2C9 gene that may influence the response to Warfarin therapy?',
|
75 |
'I am curious about the role of Herceptin in targeting the HER2/neu protein in breast cancer treatment. How does it work?',
|
76 |
'What are the common side effects associated with Lisinopril, an angiotensin-converting enzyme (ACE) inhibitor?',
|
77 |
-
'Can you explain the significance of the BCR-ABL fusion protein in the context of Imatinib therapy for chronic myeloid leukemia (CML)?',
|
78 |
'How does Ibuprofen affect the COX-2 enzyme compared to COX-1?',
|
79 |
'Are there any recent studies exploring the use of Pembrolizumab as an immune checkpoint inhibitor targeting PD-1?',
|
80 |
'I have heard about the SLC6A4 gene and its association with serotonin reuptake inhibitors (SSRIs) like Fluoxetine.',
|
|
|
67 |
import gradio as gr
|
68 |
|
69 |
exampleList = [
|
70 |
+
'Can you explain the significance of the BCR::ABL1 tyrosine kinase protein in the context of Imatinib therapy for chronic myeloid leukemia (CML)?',
|
71 |
+
'Famotidine is a histamine H2-receptor antagonist used in inpatient settings for prevention of stress ulcers and is showing increasing popularity because of its low cost.',
|
72 |
'A randomized Phase III trial demonstrated noninferiority of APF530 500 mg SC ( granisetron 10 mg ) to intravenous palonosetron 0.25 mg in preventing CINV in patients receiving MEC or HEC in acute ( 0 - 24 hours ) and delayed ( 24 - 120 hours ) settings , with activity over 120 hours .',
|
73 |
'What are the known interactions between Aspirin and the COX-1 enzyme?',
|
74 |
'Can you explain the mechanism of action of Metformin and its effect on the AMPK pathway?',
|
75 |
'Are there any genetic variations in the CYP2C9 gene that may influence the response to Warfarin therapy?',
|
76 |
'I am curious about the role of Herceptin in targeting the HER2/neu protein in breast cancer treatment. How does it work?',
|
77 |
'What are the common side effects associated with Lisinopril, an angiotensin-converting enzyme (ACE) inhibitor?',
|
|
|
78 |
'How does Ibuprofen affect the COX-2 enzyme compared to COX-1?',
|
79 |
'Are there any recent studies exploring the use of Pembrolizumab as an immune checkpoint inhibitor targeting PD-1?',
|
80 |
'I have heard about the SLC6A4 gene and its association with serotonin reuptake inhibitors (SSRIs) like Fluoxetine.',
|